BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 38,553 Shares

SR VP & CFO of BioCryst Pharmaceuticals Inc. (BCRX, Financial) Stuart Grant sells 38,553 shares of BCRX on 04/29/2010 at an average price of $8.31 a share.

Biocryst Pharmaceuticals Inc. has a market cap of $364.4 million; its shares were traded at around $8.29 with and P/S ratio of 5. Biocryst Pharmaceuticals Inc. had an annual average earning growth of 5.5% over the past 10 years.

CFO Recent Trades:

  • Sell:: SR VP & CFO Stuart Grant sold 509 shares of BCRX stock on 04/12/2010 at the average price of 8.26, the price of the stock has increased by 0.36% since.

  • Sell:: SR VP & CFO Stuart Grant sold 1,249 shares of BCRX stock on 04/05/2010 at the average price of 6.96, the price of the stock has increased by 19.11% since.

  • Sell:: SR VP & CFO Stuart Grant sold 15,000 shares of BCRX stock on 03/03/2010 at the average price of 6.96, the price of the stock has increased by 19.11% since.

  • Sell:: SR VP & CFO Stuart Grant sold 17,027 shares of BCRX stock on 01/22/2010 at the average price of 7.02, the price of the stock has increased by 18.09% since.



Directors and Officers Recent Trades:

  • Buy:: Director Charles A Sanders bought 5,000 shares of BCRX stock on 02/08/2010 at the average price of 6.66, the price of the stock has increased by 24.47% since.

  • Sell:: SR VP - CMO William P Sheridan sold 18,593 shares of BCRX stock on 04/08/2010 at the average price of 8.01, the price of the stock has increased by 3.5% since.

  • Sell:: Director Zola P Horovitz sold 10,000 shares of BCRX stock on 03/15/2010 at the average price of 7.22, the price of the stock has increased by 14.82% since.

  • Sell:: Principal Accounting Officer Mike Mills sold 1,500 shares of BCRX stock on 03/12/2010 at the average price of 7.31, the price of the stock has increased by 13.41% since.

  • Sell:: Principal Accounting Officer Mike Mills sold 5,146 shares of BCRX stock on 02/10/2010 at the average price of 7.05, the price of the stock has increased by 17.59% since.